专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2020089473A9 NOVEL AGONISTIC ANTI TNFR2 ANTIBODY MOLECULES 审中-公开
公开(公告)号：WO2020089473A9
公开(公告)日：2020-05-07
申请号：PCT/EP2019/080003
申请日：2019-11-01
申请人： BIOINVENT INTERNATIONAL AB
发明人： FRENDÉUS, Björn , TEIGE, Ingrid , MÅRTENSSON, Linda , HOLMKVIST, Petra , SEMMRICH, Monika
IPC分类号： C07K16/28 , A61P31/00 , A61K39/00
摘要： Described are novel antibody molecules that specifically bind to TNFR2 on a target cell and thereby agonize TNFR2, but that do not block the ligand TNF-α from binding to the TNFR2, Also described is the use of such antibody molecules in medicine, i.a, in treatment of cancer or chronic inflammatory diseases.

2. 发明申请

WO2020089473A3 NOVEL AGONISTIC ANTI TNFR2 ANTIBODY MOLECULES 审中-公开
公开(公告)号：WO2020089473A3
公开(公告)日：2020-05-07
申请号：PCT/EP2019/080003
申请日：2019-11-01
申请人： BIOINVENT INTERNATIONAL AB
发明人： FRENDÉUS, Björn , TEIGE, Ingrid , MÅRTENSSON, Linda , HOLMKVIST, Petra , SEMMRICH, Monika
IPC分类号： C07K16/28 , A61P31/00 , A61K39/00
摘要： Described are novel antibody molecules that specifically bind to TNFR2 on a target cell and thereby agonize TNFR2, but that do not block the ligand TNF-α from binding to the TNFR2, Also described is the use of such antibody molecules in medicine, i.a, in treatment of cancer or chronic inflammatory diseases.

3. 发明申请

WO2020049001A1 NOVEL ANTIBODIES AND NUCLEOTIDE SEQUENCES, AND USES THEREOF 审中-公开
公开(公告)号：WO2020049001A1
公开(公告)日：2020-03-12
申请号：PCT/EP2019/073488
申请日：2019-09-03
申请人： BIOINVENT INTERNATIONAL AB , TRANSGENE SA
发明人： FRENDÉUS, Björn , TEIGE, Ingrid , SEMMRICH, Monika , MÅRTENSSON, Linda , HOLMKVIST, Petra , MARCHAND, Jean-Baptiste , SILVESTRE, Nathalie
IPC分类号： C07K16/28 , A61P37/02 , A61P35/00
摘要： Described are novel anti-CTLA-4 antibody molecules and nucleotide sequences and expression vectors, such as viruses, encoding such antibody molecules. The novel antibody molecules are Treg depleting antibody molecules, and they have an improved depleting effect on CTLA-4 positive cells, such as Tregs, compared to ipilimumab. Described is also the use of such antibody molecules or nucleotide sequences or viruses in medicine, such as in the treatment of cancer, such as solid tumours.

4. 发明申请

WO2007110210A2 BIOLOGICAL MATERIALS AND USES THEREOF 审中-公开
标题翻译：生物材料及其用途
公开(公告)号：WO2007110210A2
公开(公告)日：2007-10-04
申请号：PCT/EP2007/002612
申请日：2007-03-23
申请人： BIOINVENT INTERNATIONAL AB , HOLMGREN, Lars
发明人： HOLMGREN, Lars
IPC分类号： C12N15/11 , A61P35/00
CPC分类号： C12N15/1138 , C12N2310/14
摘要： The present invention relates to prophylactic or therapeutic treatments for hindering blood vessel formation (for example, angiogenesis) for example for hindering tumour growth. In particular, the invention relates to a vaccine or medicament comprising at least one siRNA that is complementary to the nucleotide sequence encoding angiomotin or a fragment thereof. The invention also provides siRNA molecules for use in prophylactic or therapeutic treatments.
摘要翻译：本发明涉及用于阻碍血管形成（例如血管生成）的预防或治疗方法，例如阻止肿瘤生长。特别地，本发明涉及包含与编码血管动蛋白或其片段的核苷酸序列互补的至少一种siRNA的疫苗或药物。本发明还提供用于预防或治疗性治疗的siRNA分子。

5. 发明申请

WO2004081575A1 SCREENING ASSAY 审中-公开
标题翻译：筛选测试
公开(公告)号：WO2004081575A1
公开(公告)日：2004-09-23
申请号：PCT/EP2004/002566
申请日：2004-03-11
申请人： BIOINVENT INTERNATIONAL AB , NILSSON, Fredrik
发明人： NILSSON, Fredrik
IPC分类号： G01N33/68
CPC分类号： G01N33/6848 , G01N33/6842 , G01N33/6851
摘要： The present invention relates to a method for analysing a heterogeneous sample of proteins, peptides or fragments thereof, the method comprising (a) separating the heterogeneous sample of proteins, peptides or fragments thereof into heterogeneous classes by binding members of each class to a spaced apart defined location on an array, wherein members of each class have a motif common to that class; and (b) characterising the proteins, peptides or fragments thereof in each class.
摘要翻译：本发明涉及一种用于分析蛋白质，肽或其片段的异质样品的方法，所述方法包括（a）通过将每个类的成员结合到间隔开的位置将蛋白质，肽或其片段的异质样品分离成异种类别定义在阵列上的位置，其中每个类的成员具有该类共有的图案; 和（b）表征每一类中的蛋白质，肽或其片段。

6. 发明申请

WO2003068268A3 TREATMENT, DIAGNOSIS AND IMAGING OF DISEASE 审中-公开
公开(公告)号：WO2003068268A3
公开(公告)日：2003-08-21
申请号：PCT/EP2003/001461
申请日：2003-02-13
申请人： BIOINVENT INTERNATIONAL AB , EK, Sara , BORREBAECK, Carl, Arne, Krister , EHINGER, Mats
发明人： EK, Sara , BORREBAECK, Carl, Arne, Krister , EHINGER, Mats
IPC分类号： A61K47/48
摘要： The present invention provides the use of a compound comprising: (i) a binding moiety which selectively binds to a protein listed in Table 1 and (ii) a further moiety in the treatment, imaging, diagnosis or prognosis of mantle cell lymphomas (MCL). Preferably, the binding moiety is an antibody or antigenbinding fragment thereof. Advantageously, the further moiety is a directly or indirectly cytotoxic moiety or a readily detectable moiety. The invention also provides methods of imaging MCL cells, methods of diagnosing or prognosing MCL in an individual and methods of treating an individual with MCL. A further aspect of the present invention provides a method of identifying cells associated with MCL, the method comprising analyzing the pattern of gene expression in a sample of cells to be tested and comparing it to the pattern of gene expression in a sample of known MCL cells. Preferably, the cells to be tested are identified as MCL cells if the expression of one or more genes encoding a protein listed in Table 1 is upregulated compared to normal B-cells.

7. 发明申请

WO1996031539A1 ANTIBODIES AND THEIR USE IN CANCER THERAPY AND DIAGNOSIS 审中-公开
标题翻译：抗体及其在癌症治疗和诊断中的应用
公开(公告)号：WO1996031539A1
公开(公告)日：1996-10-10
申请号：PCT/GB1996000783
申请日：1996-04-01
申请人： BIOINVENT INTERNATIONAL AB , KIDDLE, Simon, John , CARLSSON, Roland , JANSSON, Bo
发明人： BIOINVENT INTERNATIONAL AB , KIDDLE, Simon, John
IPC分类号： C07K16/30
CPC分类号： C07K16/3069 , A61K38/00 , A61K47/6869
摘要： The present invention relates to antibodies, particularly to antibodies for use in cancer therapy and diagnosis, the antibodies having substantially the same binding specificity as EXT1-7C12 monoclonal antibody. This antibody is obtainable from a hybridoma cell line deposited at BCCM under reference LMBP1360CB. The antibody is shown to bind to a variety of carcinomas with a high intensity and degree of selectivity as demonstrated by immunohistochemistry analysis and cell binding assays. Compared to a panel of other monoclonal antibodies, the EXT1-7C12 antibody demonstrates a greater selectivity in binding to tumour cells, binding especially well to tumours of the ovary. The invention also includes antibodies having substantially the same binding specificity as monoclonal antibody EXT1-7C12, and mutants, derivatives, functional equivalents or fragments of the antibody. Applications of the antibodies include the therapy or diagnosis of cancer, e.g. in targeting cytotoxic compounds to cancer.
摘要翻译：本发明涉及抗体，特别是用于癌症治疗和诊断的抗体，所述抗体具有与EXT1-7C12单克隆抗体基本上相同的结合特异性。该抗体可从参考LMBP1360CB在BCCM保藏的杂交瘤细胞系获得。通过免疫组织化学分析和细胞结合测定证明抗体显示结合多种癌症具有高强度和高度的选择性。与一组其他单克隆抗体相比，EXT1-7C12抗体在结合肿瘤细胞方面表现出更大的选择性，特别是与卵巢肿瘤结合。本发明还包括具有与单克隆抗体EXT1-7C12基本上相同的结合特异性的抗体，以及抗体的突变体，衍生物，功能等同物或片段。抗体的应用包括癌症的治疗或诊断，例如。将细胞毒性化合物靶向癌症。

8. 发明申请

WO2014108456A1 USE OF ANTIBODIES AGAINST ICAM-1 IN COMBINATION WITH AN ANTI CANCER DRUG IN THE TREATMENT OF PATIENTS 审中-公开
标题翻译：在治疗患者中使用抗IC卡-1抗体与抗癌药物联合应用的抗体
公开(公告)号：WO2014108456A1
公开(公告)日：2014-07-17
申请号：PCT/EP2014/050274
申请日：2014-01-09
申请人： BIOINVENT INTERNATIONAL AB
发明人： FRENDEUS, Björn , HANSSON, Markus
IPC分类号： C07K16/28 , A61P35/00 , A61K39/395 , A61K39/00
CPC分类号： A61K39/39558 , A61K31/454 , A61K31/573 , A61K38/05 , A61K45/06 , A61K2039/505 , A61K2039/545 , C07K16/2821 , C07K2317/21 , C07K2317/73 , C07K2317/732 , A61K2300/00
摘要： There is provided antibodies or antigen-binding fragments thereof with binding specificity for ICAM-1, together with further anti-cancer agents, and compositions thereof, for use in the treatment of cancer.
摘要翻译：提供抗体或抗原结合片段与ICAM-1的结合特异性以及用于治疗癌症的其它抗癌剂及其组合物。

9. 发明申请

WO2013034904A1 ANTI-CD40 ANTIBODIES, USES AND METHODS 审中-公开
标题翻译：抗CD40抗体，用途和方法
公开(公告)号：WO2013034904A1
公开(公告)日：2013-03-14
申请号：PCT/GB2012/052179
申请日：2012-09-05
申请人： ALLIGATOR BIOSCIENCE AB , BIOINVENT INTERNATIONAL AB , ELLMARK, Peter Bo Joakim , DAHLEN, Eva Maria
发明人： ELLMARK, Peter Bo Joakim , DAHLEN, Eva Maria
IPC分类号： C07K16/28 , A61K39/395 , A61P35/00
CPC分类号： C07K16/2878 , A61K9/0019 , A61K9/0048 , A61K9/02 , A61K9/08 , A61K9/20 , A61K9/48 , A61K39/3955 , A61K49/00 , A61K51/103 , A61K51/1096 , A61K2039/505 , A61K2039/70 , C07K16/468 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/35 , C07K2317/52 , C07K2317/565 , C07K2317/622 , C07K2317/75 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to antibodies (and fragments, variants, fusions and derivatives thereof) with multivalent binding specificity for CD40, which have a potency for dendritic cell activation which is higher than, or is equal to, the potency for B cell activation and wherein the antibody, antigen-binding fragment, or fusion, variant or derivative thereof has an affinity (KD) for CD40 of less than 1x10 -10 M, which have utility in the treatment of diseases such as cancer. The invention also relates to pharmaceutical compositions, uses, methods and kits comprising such antibodies.
摘要翻译：本发明涉及对CD40具有多价结合特异性的抗体（及其片段，变体，融合物及其衍生物），其具有高于或等于B细胞活化能力的树突状细胞活化的效力，其中抗体，抗原结合片段或其融合物，变体或衍生物对于CD40的亲和力（KD）小于1×10 -10 M，其可用于治疗诸如癌症的疾病。本发明还涉及包含这种抗体的药物组合物，用途，方法和试剂盒。

10. 发明申请

WO2008075038A1 BINDING AGENTS TO THE INTEGRIN ALPHA-11 SUBUNIT 审中-公开
标题翻译：绑定代理到集成ALPHA-11子
公开(公告)号：WO2008075038A1
公开(公告)日：2008-06-26
申请号：PCT/GB2007/004875
申请日：2007-12-18
申请人： BIOINVENT INTERNATIONAL AB , FRENDÉUS, Björn , CARLSSON, Roland , JANSSON, Bo
发明人： FRENDÉUS, Björn , CARLSSON, Roland , JANSSON, Bo
IPC分类号： C07K16/28 , A61K39/395 , A61K47/48 , A61K51/10 , A61P19/02 , A61P37/00
CPC分类号： C07K16/2839 , A61K2039/505 , C07K2317/21 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/622
摘要： The present invention relates to an antibody, or antigen-binding fragment thereof, with binding specificity for an integrin α11 subunit, or a heterodimer thereof, or a variant, fusion, derivative or polypeptide chain thereof, or a fusion of a said variant or derivative thereof, which retains the binding specificity of the parent antibody wherein the antibody or antigen-binding fragment, or variant, fusion, derivative or polypeptide chain thereof, comprises the following amino acid sequences of SEQ ID NOS: 1 to 6. In particular, the invention relates to antibodies or antigen-binding fragments, or variants, fusions or derivatives thereof, with efficacy in the treatment of inflammatory disorders such as arthritic diseases ( e.g. RA and OA). The invention further provides pharmaceutical compositions and kits comprising the same.
摘要翻译：本发明涉及对整联蛋白a11亚基或其异源二聚体或其变体，融合，衍生物或多肽链或所述变体或衍生物的融合物具有结合特异性的抗体或其抗原结合片段其保留亲本抗体的结合特异性，其中抗体或抗原结合片段或其变体，融合物，衍生物或多肽链包含SEQ ID NO：1至6的以下氨基酸序列。特别地，本发明涉及在治疗诸如关节炎疾病（例如RA和OA）的炎症性疾病中有效的抗体或抗原结合片段或变体，融合物或其衍生物。本发明还提供药物组合物和包含该组合物的试剂盒。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式